Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Swedish Orphan Biovitrum Ab (OP: BIOVF )

27.23 UNCHANGED
Streaming Delayed Price Updated: 11:15 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 27.23
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 27.23
Today's Range 27.23 - 27.23
52wk Range 22.87 - 32.25
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merck Virus Treatment Shows 60.4% Effectiveness, Reduces Certain Infections In Infants
Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV. 
Via Benzinga
Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan for C3 glomerulopathy and IC-MPGN. The study met primary and secondary... 
Via Benzinga

Performance

YTD
+3.73%
+3.73%
1 Month
-13.22%
-13.22%
3 Month
-12.95%
-12.95%
6 Month
+3.30%
+3.30%
1 Year
+16.62%
+16.62%

More News

Read More
Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants
Via Benzinga
Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon
Via Benzinga
Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study
Via Benzinga
Sanofi's Hemophilia Candidate Goes Under Priority FDA Review
Via Benzinga
ADC Therapeutics, Sobi Ink European Licensing Pact For Lymphoma Drug
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Via Benzinga
Why Shares of CTI BioPharma Are Soaring Wednesday
Via The Motley Fool
European Swedish Orphan Biovitrum To Acquire CTI BioPharma For $1.7B
Via Benzinga
Selecta, SOBI's Chronic Refractory Gout Program Meets Primary Goal, US Submission Expected Next Year
Via Benzinga
Veru Stock Could Retrace Week's 45% Gain As FDA Panel Votes Against COVID-19 Drug
Via Benzinga
Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants
Via Benzinga
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
Via Benzinga
SOBI-Sanofi Partnered Hemophilia Therapy Shows Superior Bleed Protection Than Prior Prophylaxis
Via Benzinga
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
Via Benzinga
Sanofi-SOBI Hemophilia Candidate Aces Late-Stage Study In Pretreated Patients
Via Benzinga
Apellis - Sobi's Pegcetacoplan Wins European Approval For Rare Blood Disorder
Via Benzinga
AstraZeneca Blocks SOBI's $8B Buyout, Advent Withdraws The Bid - Report
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.